Last reviewed · How we verify
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
Details
| Lead sponsor | Viridian Therapeutics, Inc. |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 188 |
| Start date | Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Jul 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Thyroid Eye Disease
Interventions
- Veligrotug (VRDN-001)
- Placebo
Countries
France, United Kingdom, Germany, Hungary, Poland, Australia, United States, Turkey (Türkiye), Spain